Get started
Cyclacel Pharmaceuticals, Inc.Cyclacel Pharmaceuticals, Inc.Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CYCC chart


Full chart

CYCC upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.08 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−11.2140 USD
Net income (FY)
‪−22.55 M‬ USD
Revenue (FY)
‪420.00 K‬ USD
Shares float
‪6.20 M‬
Beta (1Y)
−0.45

About Cyclacel Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Spiro Rombotis
Headquarters
Berkeley Heights
Website
cyclacel.com
Founded
1996
FIGI
BBG000CT3XM2
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CYCC news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CYCC is 0.3174 USD — it has decreased by −3.07% in the past 24 hours. Watch Cyclacel Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cyclacel Pharmaceuticals, Inc. stocks are traded under the ticker CYCC.
CYCC stock has fallen by −12.89% compared to the previous week, the month change is a −5.72% fall, over the last year Cyclacel Pharmaceuticals, Inc. has showed a −89.96% decrease.
We've gathered analysts' opinions on Cyclacel Pharmaceuticals, Inc. future price: according to them, CYCC price has a max estimate of 1.00 USD and a min estimate of 1.00 USD. Watch CYCC chart and read a more detailed Cyclacel Pharmaceuticals, Inc. stock forecast: see what analysts think of Cyclacel Pharmaceuticals, Inc. and suggest that you do with its stocks.
CYCC reached its all-time high on Mar 16, 2004 with the price of 2,141,785.3716 USD, and its all-time low was 0.3241 USD and was reached on Nov 21, 2024. View more price dynamics on CYCC chart.
See other stocks reaching their highest and lowest prices.
CYCC stock is 10.27% volatile and has beta coefficient of −0.45. Track Cyclacel Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cyclacel Pharmaceuticals, Inc. there?
Today Cyclacel Pharmaceuticals, Inc. has the market capitalization of ‪2.00 M‬, it has decreased by −6.93% over the last week.
Yes, you can track Cyclacel Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Cyclacel Pharmaceuticals, Inc. is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
CYCC earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.54 USD resulting in a 66.67% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about Cyclacel Pharmaceuticals, Inc. earnings.
Cyclacel Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪10.00 K‬ USD, despite the estimated figure of ‪10.00 K‬ USD. In the next quarter, revenue is expected to reach ‪10.00 K‬ USD.
CYCC net income for the last quarter is ‪−1.96 M‬ USD, while the quarter before that showed ‪−3.26 M‬ USD of net income which accounts for 39.91% change. Track more Cyclacel Pharmaceuticals, Inc. financial stats to get the full picture.
No, CYCC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cyclacel Pharmaceuticals, Inc. EBITDA is ‪−19.64 M‬ USD, and current EBITDA margin is ‪−7.21 K‬%. See more stats in Cyclacel Pharmaceuticals, Inc. financial statements.
Like other stocks, CYCC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cyclacel Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cyclacel Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cyclacel Pharmaceuticals, Inc. stock shows the sell signal. See more of Cyclacel Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.